Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 8:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 4,097 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuromuscular Disorder Clear all
Withdrawn Phase 3 Interventional

Effectiveness of Transverse Abdominus Plane Catheter Blocks to Patient-controlled Analgesia in Laparoscopic Colon Resections

NCT01592630
View directory record Official record
Conditions
Colorectal Disorders, Observation of Neuromuscular Block
Interventions
0.2% ropivacaine, Saline
Drug
Lead sponsor
Stamford Hospital
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

NCT03325881
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years to 12 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
41
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Oct 16, 2026, 8:14 AM EDT
Enrolling by invitation No phase listed Observational

Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1

NCT05238909
View directory record Official record
Conditions
Neurofibromatosis 1, NF1, Neurofibromatosis Type 1
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

NCT01963598
View directory record Official record
Conditions
Sarcopenia
Interventions
REGN1033 (SAR391786), placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
70 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Anniston, Alabama • Phoenix, Arizona • El Cajon, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 16, 2026, 8:14 AM EDT
Completed No phase listed Observational

Online Survey on Computer Password Usage.

NCT00357136
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
password usage
Behavioral
Lead sponsor
Towson University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 25, 2014 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Phase 3 Interventional Results available

Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT00220740
View directory record Official record
Conditions
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
Drug
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
6
States / cities
New Haven, Connecticut • St Louis, Missouri • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

NCT05695950
View directory record Official record
Conditions
Dermatomyositis
Interventions
GLPG3667, Placebo
Drug
Lead sponsor
Lakefront Biotherapeutics NV
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
8
States / cities
Scottsdale, Arizona • Upland, California • Kendall, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 16, 2026, 8:14 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas

NCT04924608
View directory record Official record
Conditions
Neurofibromatosis 1, Plexiform Neurofibroma (PN)
Interventions
Selumetinib, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
4
States / cities
Gainesville, Florida • Rockville, Maryland • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Not applicable Interventional

Remote Gamified Sensory Perceptual Training for Patients With Fibromyalgia: a Feasibility Trial

NCT04919525
View directory record Official record
Conditions
Fibromyalgia
Interventions
TrainPain
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 16, 2026, 8:14 AM EDT
Withdrawn Not applicable Interventional

Surgical Treatments for Neuroma Pain in Amputees

NCT04204668
View directory record Official record
Conditions
Pain, Neuropathic, Amputation Neuroma, Phantom Limb Pain
Interventions
TMR, RPNI, VDMT
Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 16, 2026, 8:14 AM EDT
Not yet recruiting Not applicable Interventional

Effects of taVNS on Fibromyalgia Pain

NCT06193317
View directory record Official record
Conditions
Fibromyalgia, Pain
Interventions
Transauricular vagus nerve stimulation (taVNS)
Device
Lead sponsor
Spaulding Rehabilitation Hospital
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 16, 2026, 8:14 AM EDT
Completed No phase listed Observational

Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF)

NCT01437891
View directory record Official record
Conditions
Post-traumatic Stress Disorder, Persian Gulf Syndrome
Interventions
Not listed
Lead sponsor
Stephanie Pavlik
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2012 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Phase 4 Interventional Results available

Sugammadex Titration in Cardiac Surgery Patients

NCT05246397
View directory record Official record
Conditions
Coronary Artery Disease, Valvular Heart Disease, Aorta Disease, Heart Failure
Interventions
Sugammadex administration
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Phase 4 Interventional

Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome

NCT00610610
View directory record Official record
Conditions
Fibromyalgia Syndrome
Interventions
Paroxetine CR, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
2
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Not applicable Interventional Results available

Management Strategies for Patients With Low Back Pain and Sciatica

NCT02391350
View directory record Official record
Conditions
Low Back Pain, Sciatica, Physical Therapy
Interventions
Education and re-assurance, Physical Therapy
Behavioral · Procedure
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 60 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 22, 2021 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)

NCT02288091
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Inosine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 16, 2026, 8:14 AM EDT
Recruiting Phase 1 Interventional

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

NCT04222413
View directory record Official record
Conditions
Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Colorectal Neoplasms
Interventions
Metarrestin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Fairway, Kansas • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 8:14 AM EDT
Recruiting Phase 1Phase 2 Interventional

Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

NCT04906460
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
WVE-N531
Drug
Lead sponsor
Wave Life Sciences USA, Inc.
Industry
Eligibility
4 Years to 18 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Little Rock, Arkansas • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of GRT9906 Tablets Compared to Placebo in Patients With Fibromyalgia

NCT03783910
View directory record Official record
Conditions
Primary Fibromyalgia
Interventions
GRT9906, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
6
States / cities
DeLand, Florida • Charlotte, North Carolina • Medford, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2018 · Synced Oct 16, 2026, 8:14 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

NCT05309668
View directory record Official record
Conditions
Neurofibromatosis Type 1
Interventions
Selumetinib granule formulation, Selumetinib capsule formulation
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
1 Year to 6 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
4
States / cities
Akron, Ohio • Philadelphia, Pennsylvania • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 16, 2026, 8:14 AM EDT
Active, not recruiting Phase 1 Interventional

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT04483778
View directory record Official record
Conditions
Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma, Melanoma
Interventions
second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
0 Years to 26 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 16, 2026, 8:14 AM EDT
Recruiting Not applicable Interventional

Procedural Framing and Epidural Steroid Injection Outcomes

NCT07498140
View directory record Official record
Conditions
Lumbosacral Radiculopathy
Interventions
Behavioral manipulation of ESI expectations, No behavioral manipulation of ESI expectations, No behavioral manipulation of pharmacotherapy expectations
Behavioral · Other
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Phase 2Phase 3 Interventional

TempTouch IR Thermometry & Diabetic Patient Self-Care

NCT00289497
View directory record Official record
Conditions
Diabetic Polyneuropathy, Diabetic Foot Ulcer, Diabetes, Foot Infection
Interventions
TempTouch®
Device
Lead sponsor
Diabetica Solutions Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
3
States / cities
New Braunfels, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2006 · Synced Oct 16, 2026, 8:14 AM EDT
Completed Phase 2 Interventional Results available

The Effect of RNS60 on ALS Biomarkers

NCT03456882
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
RNS60
Drug
Lead sponsor
Mario Negri Institute for Pharmacological Research
Other
Eligibility
18 Years to 80 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 16, 2026, 8:14 AM EDT